Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients ...
American Association of Individual Investors4h
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Alvotech Stock?
Learn more about whether ACADIA Pharmaceuticals Inc. or Alvotech is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Medical Dialogues6h
Certain biologics May Reduce Infection Risk among elderly with Psoriasis: JAMA
A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...
Rheumatology Advisor8h
High Prevalence of Degenerative Disc Disease in Young Adults With Psoriatic Arthritis
Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.
Rheumatology Advisor8h
Abatacept Not Linked to Higher Malignancy Risk in RA and PsA Clinical Trials
Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.
J&J highlights Tremfya’s efficacy against psoriatic arthritis in Phase 3 trial win
Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.
Medscape12h
Secukinumab May Protect Against Bone Erosion in PsA
Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...